A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer. The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort. Part II- Expansion cohort: A total of 12 HER2-expressing breast cancer patients is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be adm

Trial Details

NCT ID
NCT05143970
Phase
PHASE1
Sponsor
Institut Paoli-Calmettes
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
Locations (sample)
  • Marseille, France|43.29695,5.38107

Key Eligibility Criteria

  • Patients with incurable advanced and/or metastatic cancer.
  • Patients with any of the following cancers:
  • In dose escalation: carcinoma of the breast, stomach, esophagus, pancreas, endometrium, ovary or lung.
  • In cohort expansion : carcinoma of the breast that expresses HER2. Eligibility is based on HER2 expression as determined locally. HER2-positive is …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →